ozekibart (INBRX-109) Phase 2 Trial

Phase 2 Randomized Study of the Tetravalent DR5 Agonist ozekibart (INBRX-109) in Patients With Unresectable or Metastatic Conventional Chondrosarcoma

ClinicalTrials.gov
Inbrx 109 P2

Key Eligibility Criteria:

+ Conventional chondrosarcoma, unresectable or metastatic
+ Available archival tissue or fresh tumor biopsy
+ Radiographic progression per RECIST 1.1 within 6 months of study treatment initiation
+ Adequate hepatic function
+ No chronic liver diseases; Exception: Patients with fatty liver disease are acceptable as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed
+ No clinically significant or uncontrolled comorbidities

Click on the interactive world map to view where this study is currently enrolling patients.